AbCellera Partners with Vertex to Develop T-Cell Engagers for Autoimmune Diseases
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
AbCellera has announced a collaboration with Vertex to discover multispecific T-cell engagers aimed at treating autoimmune diseases and other conditions. This partnership adds to Vertex's ongoing efforts to diversify its portfolio, which has been heavily focused on cystic fibrosis medications.
The collaboration reflects a growing trend in the biopharma industry towards innovative T-cell engagers, enhancing Vertex's capabilities in this area. This strategic move is expected to bolster Vertex's business as it seeks to expand beyond its current reliance on cystic fibrosis treatments.
Sources
Every quote below is verbatim from the article it is attributed to.
“AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions”
SEC Filing — AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
“The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.”
biopharma dive — AbCellera, Vertex partner on next-gen T-cell engagers